Denali Therapeutics Inc.
Denali Therapeutics Inc. is listed today as Denali Therapeutics Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2024 | $500 M | Private placement after listing | $250 million to $1 billion | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Denali Therapeutics Inc., its revenue in fiscal 2023 came from these business segments: Therapeutics $330.53 million (100%).
Annual report (SEC XBRL) · Dec 2023
Denali Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2024).
SEC Form D · Mar 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · Mar 2024
Products and services#
No products or services of Denali Therapeutics Inc. are on record.
Investors#
17 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Akdl, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| ARCH Venture Fund VIII, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| ARCH Venture Partners VIII, LLC | Venture capital | not stated | not stated | Held Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| ARCH Venture Partners VIII, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Bratton Capital Inc. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Bratton Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Crestline Investors, Inc. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Crestline Management, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Crestline SI (GP), L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| FIL Ltd | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Flagship Ventures Fund V General Partner LLC | Venture capital | not stated | not stated | Held Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Flagship Ventures Fund V, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Fmr LLC | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Marc Tessier-Lavigne | Person | not stated | not stated | Held Series A-1 preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Neuro Line Partners LP | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Ryan J. Watts | Person | not stated | not stated | Held Series B-1 preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Vicki L. Sato | Person | not stated | not stated | Held Series A-1 preferred stock, director (Form 3, 2017) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Denali Therapeutics Inc. shares, as of Sep 30, 2026.
- T. Rowe Price Investment Management, Inc.$405 M12.24%
- BlackRock, Inc.$296 M8.94%
- Baillie Gifford & Co$230 M6.94%
- Temasek Holdings (Private) Ltd$145 M4.38%
- Vanguard Portfolio Management LLC$140 M4.22%
- Vanguard Capital Management LLC$140 M4.21%
- State Street Corp$138 M4.17%
- FMR LLC$94 M2.83%
- Geode Capital Management, LLC$83 M2.52%
- Goldman Sachs Group Inc$78 M2.34%
- Baker Bros. Advisors LP$77 M2.33%
- UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC$67 M2.03%
- Price T Rowe Associates Inc /MD/$61 M1.85%
- Dimensional Fund Advisors LP$60 M1.82%
- Alliancebernstein L.P.$53 M1.61%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Alexander O. Schuth | Executive officer | Mar 2024 |
| Carole O. Ho | Executive officer | Mar 2024 |
| Ryan Watts | Executive officer | Mar 2024 |
| David P. Schenkein | Director | Mar 2024 |
| Erik T. Harris | Director | Mar 2024 |
| Jay T. Flatley | Director | Mar 2024 |
| Jennifer O. Cook | Director | Mar 2024 |
| Marc P. Tessier-Lavigne | Director | Mar 2024 |
| Nancy A. Thornberry | Director | Mar 2024 |
| Peter S. Klein | Director | Mar 2024 |
| Ryan Watts | Director | Mar 2024 |
| Steve E. Krognes | Director | Mar 2024 |
| Vicki L. Sato | Director | Mar 2024 |
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.